{"id":396642,"date":"2020-03-12T00:00:00","date_gmt":"2020-03-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoop0003-2020-biopharma-dry-and-wet-age-related-macular-degeneration-special-topics-beovu-three-months-postlaunch-for\/"},"modified":"2026-04-17T23:36:33","modified_gmt":"2026-04-17T23:36:33","slug":"sptoop0003-2020-biopharma-dry-and-wet-age-related-macular-degeneration-special-topics-beovu-three-months-postlaunch-for","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptoop0003-2020-biopharma-dry-and-wet-age-related-macular-degeneration-special-topics-beovu-three-months-postlaunch-for\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration | Special Topics | Beovu: Three Months Postlaunch for Wet AMD | US | 2020"},"content":{"rendered":"<p>Novartis\u2019s Beovu (brolucizumab-dbll) is the fourth vascular endothelial growth factor\u00a0(VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United States and the first\u00a0 product to launch for this indication since Eylea in 2011. Beovu offers the potential for dosing once every 12 weeks immediately after the first three monthly doses, giving the product a dosing advantage over Lucentis and Eylea in its product labeling. Additionally, Beovu was found to be superior to Eylea\u00a0in\u00a0improving some\u00a0anatomical outcomes in pivotal clinical trials. A competitive price from Novartis, coupled with the possibility of a less-burdensome dosing frequency, will likely ease Beovu\u2019s incorporation into clinical practice. This report provides a snapshot of Beovu\u2019s performance based on physician responses three months after its launch.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are\u00a0the awareness of, familiarity with, and perceptions related to Beovu among U.S. ophthalmologists \/ retinal specialists three months after launch?<\/li>\n<li>Is Beovu being prescribed to treatment-naive patients or as a switch therapy? What are the reasons for prescribing Beovu\u00a0for\u00a0wet AMD, and how satisfied are prescribers with the product?<\/li>\n<li>What are the main obstacles holding physicians back from administering Beovu to more of their wet AMD patients? Why have some physicians not yet used Beovu for wet AMD?<\/li>\n<li>What promotional messages and activities is\u00a0Novartis using to\u00a0support\u00a0Beovu\u2019s launch for\u00a0wet AMD?<\/li>\n<\/ul>\n<p><strong>CONTENT HIGHLIGHTS<\/strong><\/p>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Primary Research: <\/strong>Survey of 75 U.S. ophthalmologists \/ retinal specialists in January 2020<\/p>\n<p><strong>Key metrics included:<\/strong> Unaided and aided awareness of Beovu; familiarity with and impressions of Beovu; prescriber and nonprescriber profiles; willingness to prescribe Beovu; performance of Beovu on key attributes; sales representative visit frequency, reach, and effectiveness; benchmarking against Eylea<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>DRG\u2019s <em>Special Topics<\/em> reports assess key trends in dynamic disease areas. Here we provide a snapshot of Beovu\u2019s performance at three months postlaunch in the U.S. wet AMD market. Specifically, we assess U.S. physicians\u2019 awareness, perceptions, and usage of Beovu, as well as its\u00a0current and future impact on competitor therapies and the overall market. Insight is also provided on promotional efforts by Novartis, prescriber and nonprescriber profiles, and benchmarking against Eylea three months after it launched for wet AMD.<\/p>\n","protected":false},"template":"","class_list":["post-396642","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396642\/revisions"}],"predecessor-version":[{"id":396994,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/396642\/revisions\/396994"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=396642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}